



abt

AQUA BIO TECHNOLOGY ASA

Results Presentation
First Quarter 2016

11 May 2016

Technology by nature


First quarter highlights

- Continued strong financial performance
 - *All time high quarterly revenues; NOK 12.5 million*
 - *49 per cent EBITDA margin*
- Technology platform expanded
 - *Two partnerships established in Q1*
- Legal complaint filed by Access Business Group (affiliated to Amway) in New York


Income statement

<i>NOK million</i>	<i>Q1 2016</i>	<i>Q1 2015</i>	<i>FY 2015</i>
Income	12.5	9.1	38.9
Operating costs	-6.4	-3.9	-17.7
EBITDA	6.1	5.2	21.2
EBIT	4.7	3.6	15.4
EBT	4.6	4.1	15.0
Net result	3.4	4.1	17.4
EBITDA margin	48.9%	57.7%	54.5%

Revenue and profitability development




Revenues



EBITDA

Cash development



- NOK 49.7 million cash holding per 31 March 2016
- Cash holding nearly doubled over last two years
- Q2 2015: Dividend payment of NOK 6.4 million
- Q2 2016: Proposed dividend payment of NOK 10.3 million

Balance sheet

<i>NOK million</i>	<i>31 Mar 2016</i>	<i>31 Dec 2015</i>	<i>31 Mar 2015</i>
Fixed assets	8.4	11.1	11.3
Current assets	83.1	75.0	67.2
- of which is cash	49.7	42.0	33.8
Total equity	80.1	76.7	70.4
Long term debt	4.9	5.0	5.6
Short term debt	6.4	4.3	2.5
Total balance	91.5	86.1	78.5
Equity ratio	87.6%	89.1%	89.7%

Cash flow

<i>NOK million (year to date)</i>	<i>2015</i>	<i>2014</i>
Cash at beginning of period	42.0	29.2
From operations	7.8	4.7
From investments	0.1	-0.5
From financing	-0.1	-0.1
Currency effects	-0.1	0.5
Cash at end of period	49.7	33.8
Cash change in period	7.8	4.1

A strategy for growth



Two additional technologies secured in Q1



- Partner: AlgoSource Group of France
- Spirulsat®; substance based on bluegreen algae spirulina
- Substance has strong antioxidant properties, already in use in food supplement
- Testing and documentation of efficacy and safety initiated
- Product launch expected in Q4 2016
- No up front payment, ABT carries testing and commercialization costs, Algosource to receive royalty of future sales
- Red algae technology included in agreement to be tested at a later stage



- Partner: Zembra Ltd of UK
- Extract from abundant biomass after olive oil pressing
- Substance has exfoliating properties, already in use in several other applications
- Testing and documentation of efficacy and safety initiated
- Product launch expected in Q4 2016
- No up front payment, ABT carries testing and commercialization costs, Zembra to receive royalty of future sales

U.S. lawsuit unresolved

- Legal complaint filed by Access Business Group International (affiliated with Amway) in New York in March 2016
- 2012 contract expired at year-end 2015
- Disagreement on terms for any product after 1 January, 2016
- Access claims breach of contract, among other claims
- Court denied motion for Temporary Restraining Order against ABT
- Preliminary Injunction Hearing scheduled for 31 May and 1 June, 2016
- Out of court dialogue between the parties initiated

Outlook

- Revenue stream from Aquabeautine XL expected to remain steady in 2016
- Testing and documentation of the first third party products to be completed in Q3 2016
- New product launches expected in Q4 2016
- Near term opex will be affected by legal costs
- Additional in-licensing agreements to be expected throughout 2016

Welcome back

abt

AQUA BIO TECHNOLOGY ASA

Results Presentation
Second Quarter 2016

17 August 2016

Technology by nature